Pyridazine and pyridazinone derivatives as potent and selective factor XIa inhibitors.
Hu, Z., Wang, C., Han, W., Rossi, K.A., Bozarth, J.M., Wu, Y., Sheriff, S., Myers, J.E., Luettgen, J.M., Seiffert, D.A., Wexler, R.R., Quan, M.L.(2018) Bioorg Med Chem Lett 28: 987-992
- PubMed: 29501396 
- DOI: https://doi.org/10.1016/j.bmcl.2018.02.049
- Primary Citation of Related Structures:  
6C0S - PubMed Abstract: 
Pyridazine and pyridazinone derivatives were designed and synthesized as coagulation factor XIa inhibitors. Potent and selective inhibitors with single digit nanomolar affinity for factor XIa were discovered. Selected inhibitors demonstrated moderate oral bioavailability.
Organizational Affiliation: 
Bristol-Myers Squibb Company, Research and Development, 350 Carter Road, Hopewell, NJ 08540, United States. Electronic address: zilun.hu@bms.com.